MEP16808A - Supstituisana jedinjenja benzimidazola i njihova primjena u liječenju raka - Google Patents
Supstituisana jedinjenja benzimidazola i njihova primjena u liječenju rakaInfo
- Publication number
- MEP16808A MEP16808A MEP-168/08A MEP16808A MEP16808A ME P16808 A MEP16808 A ME P16808A ME P16808 A MEP16808 A ME P16808A ME P16808 A MEP16808 A ME P16808A
- Authority
- ME
- Montenegro
- Prior art keywords
- cancer treatment
- substituted compounds
- benzimidazol
- benzimidazol substituted
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
- C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01402460A EP1298125A1 (en) | 2001-09-26 | 2001-09-26 | Substituted benzimidazole compounds and their use for the treatment of cancer |
| PCT/EP2002/011353 WO2003028721A2 (en) | 2001-09-26 | 2002-09-26 | Substituted benzimidazole compounds and their use for the treatment of cancer |
| YUP-214/04A RS50896B (sr) | 2001-09-26 | 2002-09-26 | Supstituisana jedinjenja benzimidazola i njihova primena u lečenju raka |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MEP16808A true MEP16808A (bs) | 2010-06-10 |
Family
ID=8182891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-168/08A MEP16808A (bs) | 2001-09-26 | 2002-09-26 | Supstituisana jedinjenja benzimidazola i njihova primjena u liječenju raka |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US7041668B2 (sr) |
| EP (2) | EP1298125A1 (sr) |
| JP (1) | JP4510450B2 (sr) |
| KR (1) | KR100891439B1 (sr) |
| CN (1) | CN100346786C (sr) |
| AR (1) | AR037096A1 (sr) |
| AT (1) | ATE386517T1 (sr) |
| AU (1) | AU2002337151B2 (sr) |
| BR (1) | BR0212856A (sr) |
| CA (1) | CA2461622C (sr) |
| CO (1) | CO5570675A2 (sr) |
| CY (1) | CY1107953T1 (sr) |
| DE (1) | DE60225159T2 (sr) |
| DK (1) | DK1432417T3 (sr) |
| EA (1) | EA006802B1 (sr) |
| ES (1) | ES2301682T3 (sr) |
| GT (1) | GT200200190A (sr) |
| HR (1) | HRPK20040293B3 (sr) |
| HU (1) | HUP0401756A3 (sr) |
| IL (1) | IL161059A0 (sr) |
| ME (1) | MEP16808A (sr) |
| MX (1) | MXPA04002042A (sr) |
| MY (1) | MY135339A (sr) |
| NO (1) | NO327008B1 (sr) |
| NZ (1) | NZ531246A (sr) |
| PA (1) | PA8555501A1 (sr) |
| PE (1) | PE20030427A1 (sr) |
| PL (1) | PL369527A1 (sr) |
| PT (1) | PT1432417E (sr) |
| PY (1) | PY0223362A (sr) |
| RS (1) | RS50896B (sr) |
| SI (1) | SI1432417T1 (sr) |
| UY (1) | UY27452A1 (sr) |
| WO (1) | WO2003028721A2 (sr) |
| ZA (1) | ZA200401887B (sr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070010573A1 (en) | 2003-06-23 | 2007-01-11 | Xianqi Kong | Methods and compositions for treating amyloid-related diseases |
| AU2011250847B2 (en) * | 2003-06-23 | 2013-06-20 | Bhi Limited Partnership | Methods and compositions for treating amyloid-related diseases |
| EP1678121A4 (en) * | 2003-10-24 | 2007-07-25 | Exelixis Inc | MODULATORS OF TAO KINASES AND METHODS OF USE |
| DE102004010207A1 (de) | 2004-03-02 | 2005-09-15 | Aventis Pharma S.A. | Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate |
| FR2868421B1 (fr) * | 2004-04-01 | 2008-08-01 | Aventis Pharma Sa | Nouveaux benzothiazoles et leur utilisation comme medicaments |
| EP1598348A1 (en) | 2004-05-18 | 2005-11-23 | Aventis Pharma Deutschland GmbH | Novel pyridazinone derivatives as inhibitors of CDK2 |
| WO2006085149A2 (en) | 2004-12-22 | 2006-08-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| UA92180C2 (en) * | 2005-09-06 | 2010-10-11 | Смиткляйн Бичам Корпорейшн | Benzimidazole thiophene compounds as plk inhibitors |
| FR2891273B1 (fr) * | 2005-09-27 | 2007-11-23 | Aventis Pharma Sa | NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet |
| PT2089417E (pt) | 2006-10-12 | 2015-04-14 | Bhi Ltd Partnership | Métodos, compostos, composições e veículos para administrar o ácido 3-amino-1-propanossulfónico |
| PA8792501A1 (es) | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
| SG185297A1 (en) * | 2007-10-12 | 2012-11-29 | Abbott Lab | 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1 |
| FR2922550B1 (fr) | 2007-10-19 | 2009-11-27 | Sanofi Aventis | Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet |
| FR2941951B1 (fr) | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| FR2941952B1 (fr) | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| FR2941949B1 (fr) | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| FR2941950B1 (fr) | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| WO2011091152A1 (en) * | 2010-01-22 | 2011-07-28 | Pablo Gastaminza | Inhibitors of hepatitis c virus infection |
| US10125369B2 (en) | 2012-12-05 | 2018-11-13 | Alnylam Pharmaceuticals, Inc. | PCSK9 iRNA compositions and methods of use thereof |
| CN118697894A (zh) | 2015-08-25 | 2024-09-27 | 阿尔尼拉姆医药品有限公司 | 用于治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2441201C2 (de) * | 1974-08-28 | 1986-08-07 | Hoechst Ag, 6230 Frankfurt | Anthelminthisch wirksame 2-Carbalkoxyamino-5(6)-phenyl-sulfonyloxy-benzimidazole und Verfahren zu ihrer Herstellung |
| DE2541752A1 (de) | 1975-09-19 | 1977-03-24 | Hoechst Ag | Anthelminthisch wirksame 2-carbalkoxyamino-5(6)-phenyl-sulfonyloxy- benzimidazole und verfahren zu ihrer herstellung |
| DE3247615A1 (de) * | 1982-12-23 | 1984-07-05 | Hoechst Ag, 6230 Frankfurt | Substituierte phenylsulfonyloxybenzimidazolcarbaminate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| GB9900752D0 (en) * | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| US6693125B2 (en) * | 2001-01-24 | 2004-02-17 | Combinatorx Incorporated | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders |
-
2001
- 2001-09-26 EP EP01402460A patent/EP1298125A1/en not_active Withdrawn
-
2002
- 2002-09-17 PE PE2002000913A patent/PE20030427A1/es not_active Application Discontinuation
- 2002-09-24 UY UY27452A patent/UY27452A1/es unknown
- 2002-09-25 GT GT200200190A patent/GT200200190A/es unknown
- 2002-09-25 PY PY200200223362A patent/PY0223362A/es unknown
- 2002-09-25 MY MYPI20023586A patent/MY135339A/en unknown
- 2002-09-26 PT PT02772370T patent/PT1432417E/pt unknown
- 2002-09-26 DK DK02772370T patent/DK1432417T3/da active
- 2002-09-26 PL PL02369527A patent/PL369527A1/xx not_active Application Discontinuation
- 2002-09-26 HR HR20040293A patent/HRPK20040293B3/xx not_active IP Right Cessation
- 2002-09-26 ME MEP-168/08A patent/MEP16808A/xx unknown
- 2002-09-26 AU AU2002337151A patent/AU2002337151B2/en not_active Ceased
- 2002-09-26 HU HU0401756A patent/HUP0401756A3/hu unknown
- 2002-09-26 DE DE60225159T patent/DE60225159T2/de not_active Expired - Lifetime
- 2002-09-26 BR BR0212856-0A patent/BR0212856A/pt not_active IP Right Cessation
- 2002-09-26 EP EP02772370A patent/EP1432417B1/en not_active Expired - Lifetime
- 2002-09-26 AR ARP020103629A patent/AR037096A1/es unknown
- 2002-09-26 JP JP2003532053A patent/JP4510450B2/ja not_active Expired - Fee Related
- 2002-09-26 PA PA20028555501A patent/PA8555501A1/es unknown
- 2002-09-26 MX MXPA04002042A patent/MXPA04002042A/es active IP Right Grant
- 2002-09-26 EA EA200400475A patent/EA006802B1/ru not_active IP Right Cessation
- 2002-09-26 CN CNB028187458A patent/CN100346786C/zh not_active Expired - Fee Related
- 2002-09-26 WO PCT/EP2002/011353 patent/WO2003028721A2/en not_active Ceased
- 2002-09-26 RS YUP-214/04A patent/RS50896B/sr unknown
- 2002-09-26 ES ES02772370T patent/ES2301682T3/es not_active Expired - Lifetime
- 2002-09-26 AT AT02772370T patent/ATE386517T1/de active
- 2002-09-26 CA CA002461622A patent/CA2461622C/en not_active Expired - Fee Related
- 2002-09-26 IL IL16105902A patent/IL161059A0/xx unknown
- 2002-09-26 SI SI200230686T patent/SI1432417T1/sl unknown
- 2002-09-26 NZ NZ531246A patent/NZ531246A/en not_active IP Right Cessation
- 2002-09-26 KR KR1020047004365A patent/KR100891439B1/ko not_active Expired - Fee Related
-
2004
- 2004-03-08 ZA ZA200401887A patent/ZA200401887B/en unknown
- 2004-03-23 NO NO20041214A patent/NO327008B1/no not_active IP Right Cessation
- 2004-03-25 CO CO04028337A patent/CO5570675A2/es not_active Application Discontinuation
- 2004-03-25 US US10/808,889 patent/US7041668B2/en not_active Expired - Fee Related
-
2008
- 2008-05-20 CY CY20081100526T patent/CY1107953T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MEP16808A (bs) | Supstituisana jedinjenja benzimidazola i njihova primjena u liječenju raka | |
| MXPA05012573A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa. | |
| DE60112312D1 (de) | Imidazolderivate als raf-kinase-inhibitoren | |
| CY1106766T1 (el) | Παραγωγα πυριδινης ως αναστολεις raf κινασης | |
| EE200300475A (et) | Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis | |
| BRPI0207961A8 (pt) | Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos. | |
| MEP36208A (en) | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers | |
| NO20014560L (no) | Quinasoliner og terapautisk anvendelse derav | |
| ATE411022T1 (de) | Pyridylpyrrol-derivate als wirksame kinase-hemmer | |
| TNSN07093A1 (en) | Bicyclic amides as kinase inhibitors | |
| CR7716A (es) | Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor | |
| SV2003000925A (es) | Derivados espirotriciclicos nuevos y su uso como inhibidores de fosfodiesterasa-7 | |
| DE60220771D1 (de) | Hemmer von cyclinabhängigen kinasen als mittel gegen krebs | |
| NO20071585L (no) | Ny anvendelse av peptidforbindelser for behandling av benkreftsmerte, kjemoterapi- og nucleosidfremkalt smerte | |
| BG66080B1 (bg) | Заместени тиоацетамиди | |
| UY28130A1 (es) | Compuestos de indazol y composiciones farmaceuticaspara inhibr proteinquinasas, y procedimientos para su uso. | |
| CY1105818T1 (el) | Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου | |
| ECSP11005642A (es) | Nuevos pirazolopirimidinas como inhibidores de quinasa dependientes de ciclinas | |
| NO20055838L (no) | Aktive varianter av IL-18 bindende protein og medisinske anvendelser derav | |
| PL356784A1 (pl) | Substancja do zastosowania w leczeniu łuszczycy | |
| ATE410155T1 (de) | Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung | |
| IS6967A (is) | Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma | |
| ATE279410T1 (de) | 3-aminopyrazole als inhibitoren von cyclinabhängigen kinasen | |
| NO20022920L (no) | Nye forbindelser | |
| ATE336489T1 (de) | Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren |